Financial Times senior US business correspondent David Crow describes the cruel reality of the 25% of American cancer patients who find themselves forced to choose between the best treatments and the ones they can afford. The drug companies don’t accept responsibility, instead blaming insurance companies and pharmacy benefit managers for not passing rebates on to patients. However, rebates don’t apply to cancer medications, and the price hikes are now so widely criticized that US president Donald Trump is threatening to intervene. getAbstract recommends this analysis to anyone who believes in affordable health care for all.
In this summary, you will learn
- Why roughly 25% of American cancer patients have difficulty affording treatment,
- Who the drug companies say is to blame, and
- Why doctors must sometimes choose between the best or the most affordable options.
About the Author
David Crow is a senior US business correspondent for the Financial Times, covering telecoms, technology and pharmaceuticals.
Get the key points from this article in 10 minutes.
For your company
We help you build a culture of continuous learning.
Comment on this summary
Customers who read this summary also read
The New York Times, 2016
David Epstein and ProPublica
The Atlantic, 2017
Vincent DeVita and Elizabeth DeVita-Raeburn